Pediatric Spectral Domain Optical Coherence Tomography

Information

  • Research Project
  • 8129075
  • ApplicationId
    8129075
  • Core Project Number
    R44EY019000
  • Full Project Number
    2R44EY019000-02
  • Serial Number
    19000
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    2/1/2008 - 16 years ago
  • Project End Date
    8/31/2013 - 11 years ago
  • Program Officer Name
    WUJEK, JEROME R
  • Budget Start Date
    9/1/2011 - 13 years ago
  • Budget End Date
    11/30/2011 - 13 years ago
  • Fiscal Year
    2011
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/25/2011 - 13 years ago
Organizations

Pediatric Spectral Domain Optical Coherence Tomography

DESCRIPTION (provided by applicant): Acquiring diagnostic images of the retina in children is necessary to the prevention and treatment of pediatric eye disease, but it is often difficult due to the large range of eye shapes and sizes from preemies to older children and the inability of most children within this range to fixate. Fundus photography only provides a two- dimensional surface picture of the retina, potentially missing information about the disease state. In this Phase II Small Business Innovation Research application, Bioptigen, Inc. proposes to commercialize a handheld spectral domain optical coherence tomography imaging system targeted to meet the specific needs of pediatric patient populations, with additional applications in perioperative imaging and pre-clinical imaging. This Pediatric and Perioperative Spectral Domain Optical Coherence Tomography system (PP-SDOCT) is designed for maximal ease-of use with a non-cooperative patient base with a broad range of physical eye parameters and disease states. The aims of the proposal are to: enable rapid image acquisition through cornea range-finding for coarse alignment, range tracking for fine alignment, smooth focus adjustment for + 12D correction without affecting alignment, and improved footpedal control for hands-free image acquisition;capture wide-field of view, high- speed, and high-resolution structural and functional retinal images;and clinically validate the new product in preparation for an FDA 510(k) submission. The PP-SDOCT system will be designed with wide field of view optics (80 degrees), high axial resolution (3.2 um), high lateral resolution (6 um), a deep imaging window (3.2 mm), and high-speed acquisition (34 frames per second acquisition, processing, and display). The FDA requires clinical data to support 510(k) clearance of a Class II device. To that end, we have arranged collaborations with leading clinicians at Bascom Palmer Eye Institute, Boston Children's Hospital, Los Angeles Children's Hospital, Duke University Eye Center, and the Medical College of Wisconsin to acquire images on neonates through pre-adolescents, including normals, and patients suffering from or suspected of suffering from ROP or plus disease, retinal degenerative disease, or pediatric glaucoma. Imaging will be in the NICU, exam-under anesthesia, and on awake children. Our expectation is to exit the Phase II program with a fully developed, multi-modality, portable handheld imaging system that offers a new standard of care for a deserving, and often underserved, population. PUBLIC HEALTH RELEVANCE: Acquiring diagnostic images of the retina in children is necessary to the prevention and treatment of pediatric eye disease, but it is often difficult due to the large range of eye shapes and sizes from preemies to older children and the inability of most children within this range to focus on an imaging target during the test. Current imaging methods only provide a two-dimensional surface picture of the retina, potentially missing information about the disease state. Bioptigen is proposing the development of a handheld medical device, the Pediatric and Perioperative Spectral Domain Optical Coherence Tomography (PP-SDOCT) imaging system, which will enable photographers to rapidly acquire both depth slices and blood flow information non-invasively in pediatric eyes and could greatly aid in the research and treatment outcomes of pediatric eye disease.

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    R44
  • Administering IC
    EY
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    366732
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    867
  • Ed Inst. Type
  • Funding ICs
    NEI:366732\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOPTIGEN, INC.
  • Organization Department
  • Organization DUNS
    361420040
  • Organization City
    DURHAM
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    277093569
  • Organization District
    UNITED STATES